Medicaid vs. 340B: A Drug Pricing Clash (Sayeh Nikpay)

Health Affairs' Rob Lott interviews Sayeh Nikpay of the University of Minnesota about her recent paper exploring how The Medicaid Drug Rebate Program and the 340B Program interact in ways that can unintentionally increase costs, the adoption of cost-saving strategies to mitigate these interactions, and how policymakers can act to balance Medicaid savings with revenue impacts on 340B-participating safety-net providers.

Order the January 2026 issue of Health Affairs.

Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcast